Identifying the relevant population for neoadjuvant chemo-hormonal therapy combined with radical prostatectomy.
作者信息
Pignot Géraldine, Walz Jochen
机构信息
Service de Chirurgie Oncologique 2, Institut Paoli-Calmettes, Marseille, France.
出版信息
Gland Surg. 2020 Apr;9(2):495-497. doi: 10.21037/gs.2019.12.22.
Abstract
摘要
相似文献
1
Identifying the relevant population for neoadjuvant chemo-hormonal therapy combined with radical prostatectomy.确定新辅助化疗联合根治性前列腺切除术的相关人群。
Gland Surg. 2020 Apr;9(2):495-497. doi: 10.21037/gs.2019.12.22.
2
3
[Clinicopathological significance of neoadjuvant hormonal therapy prior to radical prostatectomy: whole section analysis].根治性前列腺切除术前行新辅助激素治疗的临床病理意义：全切片分析
Hinyokika Kiyo. 2002 Nov;48(11):719-23.
4
Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: biochemical and pathological effects.前列腺癌根治术前3个月与8个月新辅助激素治疗的随机对照研究：生化和病理效应
J Urol. 2001 Aug;166(2):500-6; discussion 506-7.
5
Is the Post-Radical Prostatectomy Gleason Score a Valid Predictor of Mortality after Neoadjuvant Hormonal Treatment?
Urol Int. 2016;96(3):302-8. doi: 10.1159/000440729. Epub 2015 Oct 7.
6
[Significance of neoadjuvant therapy before radical prostatectomy].[根治性前列腺切除术前行新辅助治疗的意义]
Urologe A. 2004 Jun;43(6):680-8. doi: 10.1007/s00120-004-0582-x.
7
[Neoadjuvant hormonal therapy for prostate cancer].[前列腺癌的新辅助激素治疗]
Gan To Kagaku Ryoho. 2001 Jul;28(7):927-33.
8
Neoadjuvant hormonal ablative therapy before radical prostatectomy: a review. Is it indicated?根治性前列腺切除术前行新辅助激素消融治疗：综述。是否有必要？
J Urol. 2000 Nov;164(5):1465-72.
9
Preliminary results of a prospective randomized study comparing radical prostatectomy versus radical prostatectomy associated with neoadjuvant hormonal combination therapy in T2-3 N0 M0 prostatic carcinoma. The European Study Group on Neoadjuvant Treatment of Prostate Cancer.一项关于T2-3 N0 M0期前列腺癌患者行根治性前列腺切除术与根治性前列腺切除术联合新辅助激素联合治疗对比的前瞻性随机研究的初步结果。欧洲前列腺癌新辅助治疗研究组。
Urology. 1997 Mar;49(3A Suppl):65-9. doi: 10.1016/s0090-4295(97)00171-4.
10
Neoadjuvant hormonal therapy and radical prostatectomy for clinical stage C carcinoma of the prostate.
Br J Urol. 1994 May;73(5):544-8. doi: 10.1111/j.1464-410x.1994.tb07641.x.
引用本文的文献
1
Neoadjuvant Androgen Deprivation Therapy Effects on Perioperative Outcomes Prior to Radical Prostatectomy: Eleven Years of Experiences at Ramathibodi Hospital.新辅助雄激素剥夺疗法对根治性前列腺切除术前围手术期结局的影响：拉玛提波迪医院11年的经验
Res Rep Urol. 2021 Jun 1;13:303-312. doi: 10.2147/RRU.S312128. eCollection 2021.
本文引用的文献
1
Neoadjuvant chemohormonal therapy combined with radical prostatectomy and extended PLND for very high risk locally advanced prostate cancer: A retrospective comparative study.新辅助化疗联合根治性前列腺切除术及扩大盆腔淋巴结清扫术治疗极高危局部晚期前列腺癌：一项回顾性比较研究
Urol Oncol. 2019 Dec;37(12):991-998. doi: 10.1016/j.urolonc.2019.07.009. Epub 2019 Aug 27.
2
Systemic treatments for high-risk localized prostate cancer.高危局限性前列腺癌的全身治疗。
Nat Rev Urol. 2018 Aug;15(8):498-510. doi: 10.1038/s41585-018-0017-x.
3
Impact of Therapy on Genomics and Transcriptomics in High-Risk Prostate Cancer Treated with Neoadjuvant Docetaxel and Androgen Deprivation Therapy.新辅助多西他赛和雄激素剥夺治疗高危前列腺癌的基因组学和转录组学治疗影响。
Clin Cancer Res. 2017 Nov 15;23(22):6802-6811. doi: 10.1158/1078-0432.CCR-17-1034. Epub 2017 Aug 25.
4
Neoadjuvant Treatment of High-Risk, Clinically Localized Prostate Cancer Prior to Radical Prostatectomy.前列腺癌根治术前高危、临床局限性前列腺癌的新辅助治疗。
Curr Urol Rep. 2016 May;17(5):37. doi: 10.1007/s11934-016-0592-4.
5
Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data.在局限性或转移性激素敏感性前列腺癌男性患者的标准治疗中添加多西他赛或双膦酸盐：汇总数据的系统评价和荟萃分析
Lancet Oncol. 2016 Feb;17(2):243-256. doi: 10.1016/S1470-2045(15)00489-1. Epub 2015 Dec 21.
6
Chemotherapy and novel therapeutics before radical prostatectomy for high-risk clinically localized prostate cancer.高危临床局限性前列腺癌根治性前列腺切除术前行化疗及新型治疗方法
Urol Oncol. 2015 May;33(5):217-25. doi: 10.1016/j.urolonc.2014.11.020. Epub 2015 Jan 14.
7
Neoadjuvant therapy for localized prostate cancer: Examining mechanism of action and efficacy within the tumor.局限性前列腺癌的新辅助治疗：研究肿瘤内的作用机制和疗效。
Urol Oncol. 2016 Apr;34(4):182-92. doi: 10.1016/j.urolonc.2013.12.001. Epub 2014 Feb 2.
8
Rationale for and review of neoadjuvant therapy prior to radical prostatectomy for patients with high-risk prostate cancer.高危前列腺癌患者根治性前列腺切除术前新辅助治疗的理由和评价。
Drugs. 2013 Sep;73(13):1417-30. doi: 10.1007/s40265-013-0107-2.
9
Time trends and local variation in primary treatment of localized prostate cancer.局限性前列腺癌的主要治疗方法的时间趋势和局部变化。
J Clin Oncol. 2010 Mar 1;28(7):1117-23. doi: 10.1200/JCO.2009.26.0133. Epub 2010 Feb 1.
10
A systematic review and meta-analysis of randomised trials of neo-adjuvant hormone therapy for localised and locally advanced prostate carcinoma.一项针对局限性和局部晚期前列腺癌新辅助激素治疗随机试验的系统评价和荟萃分析。
Cancer Treat Rev. 2009 Feb;35(1):9-17. doi: 10.1016/j.ctrv.2008.08.002. Epub 2008 Oct 15.
Zotero 插件